Christopher Kanakry, National Cancer Institute, talks on advances in approaches to prevent graft-versus-host disease (GvHD), highlighting that while several therapeutics have been found to reduce the risk and severity of acute GvHD – including abatacept and tacrolimus – few appear to have an impact on chronic GvHD. However, Dr Kanakry comments that ex vivo and in vivo T-cell depletion strategies may mitigate chronic GvHD. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.